Athira Pharma (NASDAQ:ATHA) Shares Up 1.3% – Should You Buy?

Athira Pharma, Inc. (NASDAQ:ATHA) traded up 1.3% during trading on Friday . The company traded as high as $0.32 and last traded at $0.31. 111,112 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 1,480,716 shares. The stock had previously closed at $0.30.

Athira Pharma Trading Up 1.3 %

The firm has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.51. The company has a market capitalization of $11.91 million, a price-to-earnings ratio of -0.11 and a beta of 3.00.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06. On average, sell-side analysts forecast that Athira Pharma, Inc. will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Athira Pharma stock. BML Capital Management LLC bought a new position in shares of Athira Pharma, Inc. (NASDAQ:ATHA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,775,885 shares of the company’s stock, valued at approximately $1,629,000. Athira Pharma comprises 1.0% of BML Capital Management LLC’s holdings, making the stock its 15th biggest position. BML Capital Management LLC owned about 7.18% of Athira Pharma at the end of the most recent quarter. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.